Teva Pharmaceutical Industries Ltd. issued the following statement regarding
the outstanding 1.5% Convertible Senior Notes due 2025 of Ivax Corporation,
in connection with Teva's pending acquisition of Ivax. Although it has not made
a final decision, and will not do so until following the closing of the acquisition
in accordance with the terms of the applicable indenture, Teva does not expect
to elect the "public acquirer fundamental change" option with respect
to such Notes.
Genetic Engineering News